A Phase 1 interventional study of Lumateperone Capsule and Lumateperone LAI in Schizophrenia or Schizoaffective, sponsored by Intra-Cellular Therapies, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-07-31.
Sponsored by Intra-Cellular Therapies, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing lumateperone in Schizophrenia — 3 open to participants now, 3 under way, 2 of them phase 3. lumateperone · Schizophrenia.
Among the 12 studies testing lumateperone in Schizophrenia, this one is the 7th largest by enrollment, is one of 4 that started in 2024, is one of 3 in phase 1, and was the 12th registered.
3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.
Browse Schizophrenia studies →3 of the 12 studies testing lumateperone in Schizophrenia are open now, in 3 countries. Recruiting first, the newest first:
Louisiana State University Health Sciences Center Shreveport · Sites in United States
Ages 18–65
University of Massachusetts, Worcester · Sites in United States
Ages 18–65
Intra-Cellular Therapies, Inc. · Sites in United States, Colombia, Serbia
Ages 5–17
By country, each count listing its studies:
lumateperone: first FDA approval 2019 (CAPLYTA). What it is approved for, and how studies give it, is on its page →
Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lumateperone is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 70 across 2,953 interventional studies indexed under Schizophrenia.
Median enrollment 66 across the 12 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 12 have an industry lead sponsor. The 4 most frequent:
This study is registered under Intra-Cellular Therapies, Inc., one of the names counted as Johnson & Johnson. Under that name alone:
Intra-Cellular Therapies, Inc. is the lead sponsor of 41 studies on the registry; 12 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 11 (46%) have results posted.
206 studies in Schizophrenia by Johnson & Johnson: 2 open now, 2 under way, 1 of them phase 3. Of 203 finished, 57 (28%) have results posted.
Among the 206 studies in Schizophrenia by Johnson & Johnson, this one is the 132nd largest by enrollment of the 176 interventional ones that give a count, is one of 2 that started in 2024, is one of 42 in phase 1, and was the 205th registered.
Johnson & Johnson’s Schizophrenia studies by the year they started, since 1996.
2 of the studies testing lumateperone in Schizophrenia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06482554Phase 3Louisiana State University Health Sciences Center ShreveportLumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. | 2026-12 |
| NCT06174116University of Massachusetts, WorcesterMetabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing lumateperone in Schizophrenia, from their registry updates:
Among Johnson & Johnson’s 206 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-E2 after a 5-day washout
Drug: Lumateperone Capsule · Drug: Lumateperone LAI
Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-E3 after a 5-day washout
Drug: Lumateperone Capsule · Drug: Lumateperone LAI
Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-X2 after a 5-day washout
Drug: Lumateperone Capsule · Drug: Lumateperone LAI
Lumateperone 42 mg once daily for 5 days following by a single IM dose of lumateperone 100 mg LAI formulation X500-X5 after a 5-day washout
Drug: Lumateperone Capsule · Drug: Lumateperone LAI
Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> 100 mg) of lumateperone LAI formulation (chosen from Part A) after a 5-day washout
Drug: Lumateperone Capsule · Drug: Lumateperone LAI
Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> 100 mg) of lumateperone LAI formulation (chosen from Part A) after a 5-day washout
Drug: Lumateperone Capsule · Drug: Lumateperone LAI
Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> 100 mg) of lumateperone LAI formulation (chosen from Part A) after a 5-day washout
Drug: Lumateperone Capsule · Drug: Lumateperone LAI
Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> dose in Part B) of lumateperone LAI formulation (chosen from Part B) after a 5-day washout
Drug: Lumateperone Capsule · Drug: Lumateperone LAI
Lumateperone 42 mg once daily for 5 days following by a single IM dose (\> dose in Part B) of lumateperone LAI formulation (chosen from Part B) after a 5-day washout
Drug: Lumateperone Capsule · Drug: Lumateperone LAI
Lumateperone 42 mg capsule, oral administration
Lumateperone LAI X500-E2 IM injection
Lumateperone LAI X500-E3 IM injection
Lumateperone LAI X500-X2 IM injection
Lumateperone LAI X500-X5 IM injection
Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
Pharmacokinetics: Cmax,oral
Maximum plasma concentration of lumateperone
Time frame: Day 5
Pharmacokinetics: Cmax,IM
Maximum plasma concentration of lumateperone
Time frame: Day 11-60
Pharmacokinetics: Tmax,oral
Time of maximum concentration of lumateperone in plasma
Time frame: Day 5
Pharmacokinetics: Tmax,IM
Time of maximum concentration of lumateperone in plasma
Time frame: Day 11-60
Pharmacokinetics: AUC0-t,oral
Area under the plasma concentration time curve from time zero to the last measurable of concentration of lumateperone
Time frame: Day 5
Pharmacokinetics: AUC0-t,IM
Area under the plasma concentration time curve from time zero to the last measurable of concentration of lumateperone
Time frame: Day 11-60
Percentage of subjects with treatment-emergent adverse events
Time frame: up to 30 days after the last protocol-defined study visit
Change from baseline in systolic and diastolic blood pressure
Time frame: Days 25 and 60
Change from baseline in ECG QTcF interval
Time frame: Days 25 and 60
Change from baseline in hemoglobin
Time frame: Days 25 and 60
Change from baseline in white blood cell count
Time frame: Days 25 and 60
Change from baseline in aspartate aminotransferase
Time frame: Days 25 and 60
Change from baseline in alanine aminotransferase
Time frame: Days 25 and 60
Change from baseline in Abnormal Involuntary Movement Scale (AIMS)
AIMS is a measure of facial and oral movements, extremity movements and trunk movements. Items are rated on a scale from none (0) to severe (4).
Time frame: Days 25 and 60
Ran from Aug 2024 to primary completion in Nov 2025, 14 months.
Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 14 months is above that.
Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lumateperone
Intra-Cellular Therapies, Inc. →